# Stability-Guided Formulation of a Light-Sensitive D-LSD Capsule for Clinical Investigation

**Authors:** Bernard Do, Luc Mallet, Maxime Annereau, Danielle Libong, Audrey Solgadi, Florence Vorspan, Muriel Paul, Philippe-Henri Secretan

PMC · DOI: 10.3390/pharmaceutics17060767 · Pharmaceutics · 2025-06-11

## TL;DR

This paper presents a light-stable capsule formulation of D-LSD to enable its clinical testing for treating alcohol use disorder.

## Contribution

The study introduces a photostable capsule formulation of D-LSD using advanced analytical methods to support clinical development.

## Key findings

- D-LSD in solution degrades rapidly under light, forming photoisomers and oxidative byproducts.
- The liquid-filled capsule formulation significantly reduces photodegradation under ICH-compliant conditions.
- Orthogonal analytical methods confirmed the stability and structural integrity of the formulation.

## Abstract

Background/Objectives: D-lysergic acid diethylamide (D-LSD) is under investigation as a potential therapeutic strategy for alcohol use disorder (AUD). However, the extreme light sensitivity of D-LSD presents a significant challenge in developing suitable pharmaceutical forms, particularly for clinical trial settings. This study proposes a liquid-filled capsule formulation designed to provide accurate dosing while protecting D-LSD from photodegradation. Methods: To support formulation development and ensure its suitability as an investigational medicinal product, a multi-tiered analytical strategy was employed. This included liquid chromatography coupled with ion mobility spectrometry and mass spectrometry (LC-IM-MS), along with quantum chemical calculations (density functional theory (DFT) and time dependent-DFT (TD-DFT)), to ensure robust and orthogonal structural characterization of degradation products. Results: Photostress studies demonstrated that while D-LSD in solution rapidly degrades into photoisomers and photooxidative byproducts, the capsule formulation markedly mitigates these transformations under ICH-compliant conditions. Conclusions: These findings highlight the essential role of orthogonal stability profiling in guiding formulation development and demonstrate that this approach may offer a viable, photostable platform for future clinical investigation of D-LSD in the treatment of AUD.

## Linked entities

- **Chemicals:** D-lysergic acid diethylamide (PubChem CID 5761), D-LSD (PubChem CID 5761)

## Full-text entities

- **Diseases:** AUD (MESH:D000437)
- **Chemicals:** D-LSD (MESH:D008238)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12196330/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12196330/full.md

## References

18 references — full list in the complete paper: https://tomesphere.com/paper/PMC12196330/full.md

---
Source: https://tomesphere.com/paper/PMC12196330